N-[4-amino-2-(2,4-difluoroanilino)pyrimidine-5-carboximidoyl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: N-[4-amino-2-(2,4-difluoroanilino)pyrimidine-5-carboximidoyl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide
• 化学式: C₂₈H₃₃F₂N₉O₂
• 分子量: 565.6
• InChiKey: SJEABPDHVVXECQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  41
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  147
• 氢给体数：
  4
• 氢受体数：
  11

文献信息

• [EN] DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING PAIN<br/>[FR] DÉRIVÉS DE TYPE AZA-INDAZOLE OU DIAZA-INDAZOLE POUR LE TRAITEMENT DE LA DOULEUR
  申请人：PF MEDICAMENT

  公开号：WO2014016433A1

  公开（公告）日：2014-01-30

  The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture; for use in the treatment of pain.

  本发明涉及如下式(I)的化合物：或其药用可接受的盐或溶剂化物，其构象异构体，或其立体异构体或立体异构体混合物，以任何比例，例如对映体混合物，尤其是外消旋混合物；用于治疗疼痛。
• [EN] DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING A CANCER OVEREXPRESSING TRK<br/>[FR] DÉRIVÉS DE TYPE AZA-INDAZOLE OU DIAZA-INDAZOLE POUR LE TRAITEMENT D'UN CANCER SUREXPRIMANT LA TRK
  申请人：PF MEDICAMENT

  公开号：WO2014016434A1

  公开（公告）日：2014-01-30

  The present invention relates to a compound of following formula (I) or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture, as well as pharmaceutical composition comprising such a compound, for use in the treatment of a cancer associated with the overexpression of at least one Trk protein.

  本发明涉及式(I)所示的化合物，或其药用可接受的盐或溶剂化物，其同分异构体，或其立体异构体或立体异构体混合物，以任何比例，例如对映体混合物，尤其是外消旋混合物，以及包含该化合物的药物组合物，用于治疗与至少一种Trk蛋白过表达相关的癌症。
• DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING PAIN
  申请人：PIERRE FABRE MEDICAMENT

  公开号：US20150190394A1

  公开（公告）日：2015-07-09

  The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture; for use in the treatment of pain.

  本发明涉及以下式(I)的化合物，或其药学上可接受的盐或溶剂，其互变异构体，或其立体异构体或立体异构体混合物，比例不限，例如对映体混合物，特别是外消旋混合物；用于治疗疼痛。
• DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING A CANCER OVEREXPRESSING Trk
  申请人：PIERRE FABRE MEDICAMENT

  公开号：US20150266880A1

  公开（公告）日：2015-09-24

  The present invention relates to a compound of following formula (I) or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture, as well as pharmaceutical composition comprising such a compound, for use in the treatment of a cancer associated with the overexpression of at least one Trk protein.

  本发明涉及以下式(I)的化合物或其药学上可接受的盐或溶剂、同分异构体、立体异构体或同分异构体混合物，如对映体混合物，特别是外消旋混合物，以及包含这种化合物的制药组合物，用于治疗与至少一种Trk蛋白过度表达相关的癌症。
• DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING A CANCER OVEREXPRESSING TRK
  申请人：Pierre Fabre Médicament

  公开号：EP2877176B1

  公开（公告）日：2017-04-26